No change in [ 11C]CUMI-101 binding to 5-HT 1A receptors after intravenous citalopram in human

Synapse

Volumn 66, Issue 10, 2012, Pages 880-884

  Pinborg, Lars H ^a   Feng, Ling ^a   Haahr, Mette E ^a   Gillings, Nic ^a   Dyssegaard, Agnete ^a   Madsen, Jacob ^a   Svarer, Claus ^a   Yndgaard, Stig ^a   Kjaer, Troels W ^a   Parsey, Ramin V ^b,c   Hansen, Hanne D ^a   Ettrup, Anders ^a   Paulson, Olaf B ^a,d   Knudsen, Gitte M ^a  

^a Rigshospitalet   (Denmark)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

5 HT 1A; 11C CUMI 101; Citalopram; Human; PET

Indexed keywords

CITALOPRAM; CUMI 101 C 11; RADIOPHARMACEUTICAL AGENT; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; 2 (4 (4 (2 METHOXYPHENYL)PIPERAZIN 1 YL)BUTYL) 4 METHYL 1,2,4 TRIAZINE 3,5 (2H,4H) DIONE; 2-(4-(4-(2-METHOXYPHENYL)PIPERAZIN-1-YL)BUTYL)-4-METHYL-1,2,4-TRIAZINE-3,5-(2H,4H)-DIONE; PIPERAZINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN UPTAKE INHIBITOR; TRIAZINE DERIVATIVE;

ADULT; ANTERIOR CINGULATE; ARTICLE; CHEMOSENSITIVITY; DRUG BLOOD LEVEL; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; NEOCORTEX; NORMAL HUMAN; OCCIPITAL CORTEX; ORBITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RAPHE NUCLEUS; RECEPTOR BINDING; RECEPTOR OCCUPANCY; TEMPORAL CORTEX; THALAMUS; CEREBELLUM; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; SCINTISCANNING;

ADULT; CEREBELLUM; CITALOPRAM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; TRIAZINES;

EID: 84864633330     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21579     Document Type: Article

References (32)

1. Ashburner J, Friston K. 1997. Multimodal image coregistration and partitioning-A unified framework. Neuroimage 6: 209-217.
2. Brooks DJ. 2006. Dopaminergic action beyond its effects on motor function: Imaging studies. J Neurol 253( Suppl 4): IV8-IV15.
3. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. 2010. Measuring drug occupancy in the absence of a reference region: The Lassen plot re-visited. J Cereb Blood Flow Metab 30: 46-50.
4. Gillings N. 2009. A restricted access material for rapid analysis of [(11)C]-labeled radiopharmaceuticals and their metabolites in plasma. Nucl Med Biol 36: 961-965.
5. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA. 2006. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97: 1089-1103.
6. Giovacchini G, Lang L, Ma Y, Herscovitch P, Eckelman WC, Carson RE. 2005. Differential effects of paroxetine on raphe and cortical 5-HT1A binding: A PET study in monkeys. Neuroimage 28: 238-248.
7. Hendry N, Christie I, Rabiner EA, Laruelle M, Watson J. 2011. In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue. Nucl Med Biol 38: 273-277.
8. Hines CS, Liow JS, Zanotti-Fregonara P, Hirvonen J, Morse C, Pike VW, Innis RB. 2011. Human biodistribution and dosimetry of (1)(1)C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain. PloS One 6: e25309.
9. Hinz R, Selvaraj S, Murthy NV, Bhagwagar Z, Taylor M, Cowen PJ, Grasby PM. 2008. Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls. J Cereb Blood Flow Metab 28: 1478-1490.
10. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
11. Kumar JS, Majo VJ, Hsiung SC, Millak MS, Liu KP, Tamir H, Prabhakaran J, Simpson NR, Van Heertum RL, Mann JJ, Parsey RV. 2006. Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]butyl}-4-methyl-2H-[1, 2, 4]triazine-3, 5-dione: A novel 5-HT1A receptor agonist positron emission tomography ligand. J Med Chem 49: 125-134.
12. Kumar JS, Prabhakaran J, Majo VJ, Milak MS, Hsiung SC, Tamir H, Simpson NR, Van Heertum RL, Mann JJ, Parsey RV. 2007a. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1, 2, 4-triazine -3, 5(2H, 4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging 34: 1050-1060.
13. Kumar JS, Prabhakaran J, Majo VJ, Milak MS, Hsiung SC, Tamir H, Simpson NR, Van Heertum RL, Mann JJ, Parsey RV. 2007b. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1, 2, 4-triazine-3, 5(2H, 4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging 34: 1050-1060.
14. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9240.
15. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK, Osman S, Bloomfield PM, Jones T, Patsalos PN, O'Connell MT, Duncan JS, Vanggaard Andersen J. 1995. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: Application of the steady-state principle. J Cereb Blood Flow Metab 15: 152-165.
16. McClelland GR, Raptopoulos P. 1984. EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers. Psychopharmacology (Berl) 83: 327-329.
17. Meltzer HY, Maes M. 1994. Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology (Berl) 114: 635-643.
18. Milak MS, Severance AJ, Ogden RT, Prabhakaran J, Kumar JS, Majo VJ, Mann JJ, Parsey RV. 2008. Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET. J Nucl Med 49: 587-596.
19. Milak MS, DeLorenzo C, Zanderigo F, Prabhakaran J, Kumar JS, Majo VJ, Mann JJ, Parsey RV. 2010. In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer. J Nucl Med 51: 1892-1900.
20. Milak MS, Severance AJ, Prabhakaran J, Kumar JS, Majo VJ, Ogden RT, Mann JJ, Parsey RV. 2011. In vivo serotonin-sensitive binding of [11C]CUMI-101: A serotonin 1A receptor agonist positron emission tomography radiotracer. J Cereb Blood Flow Metab 31: 243-249.
21. Mukaida K, Shichino T, Koyanagi S, Himukashi S, Fukuda K. 2007. Activity of the serotonergic system during isoflurane anesthesia. Anesth Analg 104: 836-839.
22. Narendran R, Martinez D. 2008. Cocaine abuse and sensitization of striatal dopamine transmission: A critical review of the preclinical and clinical imaging literature. Synapse 62: 851-869.
23. Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM. 2010. Measuring endogenous 5-HT release by emission tomography: Promises and pitfalls. J Cereb Blood Flow Metab 30: 1682-1706.
24. Pinborg LH, Adams KH, Yndgaard S, Hasselbalch SG, Holm S, Kristiansen H, Paulson OB, Knudsen GM. 2004. [18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge. J Cereb Blood Flow Metab 24: 1037-1045.
25. Praschak-Rieder N, Hussey D, Wilson AA, Carella A, Lee M, Dunn E, Willeit M, Bagby RM, Houle S, Meyer JH. 2004. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: An [(18)F] MPPF positron emission tomography study. Biol Psychiatry 56: 587-591.
26. Rabiner EA, Messa C, Sargent PA, Husted-Kjaer K, Montgomery A, Lawrence AD, Bench CJ, Gunn RN, Cowen P, Grasby PM. 2002. A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: Normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage 15: 620-632.
27. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, See WR. 1991. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 14: 439-447.
28. Sibon I, Benkelfat C, Gravel P, Aznavour N, Costes N, Mzengeza S, Booij L, Baker G, Soucy JP, Zimmer L, Descarries L. 2008. Decreased [18F]MPPF binding potential in the dorsal raphe nucleus after a single oral dose of fluoxetine: A positron-emission tomography study in healthy volunteers. Biol Psychiatry 63: 1135-1140.
29. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, Holm S, Paulson OB, Knudsen GM. 2005. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 24: 969-979.
30. Udo de Haes JI, Bosker FJ, Van Waarde A, Pruim J, Willemsen AT, Vaalburg W, Den Boer JA. 2002. 5-HT(1A) receptor imaging in the human brain: Effect of tryptophan depletion and infusion on [(18)F]MPPF binding. Synapse 46: 108-115.
31. Whittington R, Virag L. 2006. Isoflurane decreases extracellularserotonin in the mouse hippocampus. Anesth Analg 103: 92-98.
32. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, Seeman P, Wilson AA, Kapur S. 2008. First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 33: 279-289.